Nagasaki et al. have shown that of the 119 breast cancer patients, 59% were NR2F2 positive for immunohistochemical staining, and the positive cases correlate with a bad clinical outcome and ER-positive status [32]. Here, ESR1 is linked to breast carcinoma.